Chakraborty Chiranjib, Lo Yi-Hao, Bhattacharya Manojit, Das Arpita, Wen Zhi-Hong
Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal 700126, India.
Department of Family Medicine, Zuoying Armed Forces General Hospital, Kaohsiung 81342, Taiwan.
Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.
It has been five years since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and we are also approaching the five-year mark of the COVID-19 pandemic. The vaccine is a significant weapon in combating infectious diseases like SARS-CoV-2. Several vaccines were developed against SARS-CoV-2, and they demonstrated efficacy and safety during these five years. The rapid development of multiple next-generation vaccine candidates in different platforms with very little time is the success story of the vaccine development endeavor. This remarkable success of rapid vaccine development is a new paradigm for fast vaccine development that might help develop infectious diseases and fight against the pandemic. With the completion of five years since the beginning of SARS-CoV-2 origin, we are looking back on the five years and reviewing the milestones, vaccine platforms, animal models, clinical trials, successful collaborations, vaccine safety, real-world effectiveness, and challenges. Lessons learned during these five years will help us respond to public health emergencies and to fight the battle against future pandemics.
自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）出现以来已经过去了五年，我们也即将迎来新冠疫情的五周年。疫苗是对抗SARS-CoV-2等传染病的重要武器。针对SARS-CoV-2研发了几种疫苗，并且它们在这五年间展现出了有效性和安全性。在极短时间内，多个不同平台的下一代候选疫苗迅速发展，这是疫苗研发工作的成功典范。快速疫苗研发的这一显著成功是快速疫苗开发的新范例，可能有助于开发传染病并抗击疫情。自SARS-CoV-2起源开始至今已满五年，我们回顾这五年，审视其中的里程碑、疫苗平台、动物模型、临床试验、成功合作、疫苗安全性、实际效果以及挑战。这五年间吸取的经验教训将帮助我们应对突发公共卫生事件，并抗击未来的疫情。
